Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion
Status:
Completed
Trial end date:
2017-04-30
Target enrollment:
Participant gender:
Summary
Primary Objective: To investigate the pretreatment quantitative factors as shown in SD-OCT
images that correlate with posttreatment VA in patients who underwent intravitreal Lucentis
(Ranibizumab) for RVO.
Secondary Objectives: Correlations between posttreatment BCVA and pretreatment factors were
evaluated, including age, pretreatment BCVA, photoreceptor outer segment (PROS) length,
central foveal thickness (CFT), outer foveal thickness (OFT), and outer nuclear layer
thickness (ONLT). The factors influencing posttreatment BCVA were evaluated using multiple
regression analysis.
Detailed information on macular morphology, such as the photoreceptor IS/OS junction and ELM,
can be obtained in SD-OCT. Some OCT studies evaluated other quantitative factors in eye
disease. It was reported that PROS length was correlated with BCVA in patients with DME.¹
Other investigators suggested that the thickness, area, and volume of the outer layer were
correlated with BCVA in patients with dry age-related macular degeneration (AMD).² Outer
foveal thickness (OFT) and relative reflectivity of the outer nuclear layer (ONL) were
associated with BCVA in patients with macular hole.3, 4 The volume of the ONL was found to be
associated with BCVA in patients with AMD.5 The aim of this study was to investigate the
pretreatment quantitative factors as shown in SD-OCT images that correlate with posttreatment
VA in patients who underwent intravitreal Lucentis (Ranibizumab) for RVO.